ASCO 2020: Updates in Prostate Cancer Treatment

home / peer-exchange / asco-prostate-cancer-evolving-treatment-approaches
PSMA-Targeted Imaging in Prostate Cancer

EP. 1: PSMA-Targeted Imaging in Prostate Cancer

July 9th 2020
Conventional Versus PSMA Imaging in Prostate Cancer

EP. 2: Conventional Versus PSMA Imaging in Prostate Cancer

July 9th 2020
Data for Metastatic Castration-Sensitive Prostate Cancer

EP. 3: Data for Metastatic Castration-Sensitive Prostate Cancer

July 9th 2020
Clinical Trials in the Community Setting for Prostate Cancer

EP. 4: Clinical Trials in the Community Setting for Prostate Cancer

July 9th 2020
FDA Approved Agents for Non-Metastatic CRPC

EP. 5: FDA Approved Agents for Non-Metastatic CRPC

July 9th 2020
Overall Survival Data Presented at ASCO 2020 for nmCRPC

EP. 6: Overall Survival Data Presented at ASCO 2020 for nmCRPC

July 9th 2020
Differences Between AR-Targeted Therapy in Prostate Cancer

EP. 7: Differences Between AR-Targeted Therapy in Prostate Cancer

July 9th 2020
The CARD and PROfound Trials for Metastatic CRPC

EP. 8: The CARD and PROfound Trials for Metastatic CRPC

July 9th 2020
Impact of Clinical Data on the Treatment of mCRPC

EP. 9: Impact of Clinical Data on the Treatment of mCRPC

July 9th 2020
Genetic Testing in Metastatic CRPC

EP. 10: Genetic Testing in Metastatic CRPC

July 9th 2020
Radium-223 in Metastatic CRPC

EP. 11: Radium-223 in Metastatic CRPC

July 9th 2020
Emerging Therapies for Advanced Prostate Cancer

EP. 12: Emerging Therapies for Advanced Prostate Cancer

July 9th 2020